Moderna cancer vaccine trial begins in UK, scientists hopeful of 'dawn of a new age of treatments'

Cancer patients in the UK are part of a global trial for the mRNA therapy mRNA-4359. The phase 1/2 clinical trial, sponsored by Moderna, aims to evaluate the safety and efficacy of the therapy in treating melanoma, lung cancer, and other solid tumor cancers. The therapy uses mRNA to train the immune system to recognize and combat cancer cells expressing common tumor markers. The trial is conducted in collaboration with Moderna-UK Strategic Partnership and aims to bring mRNA vaccine manufacturing to the UK. The first patient to receive mRNA-4359 was an 81-year-old man with treatment-resistant malignant melanoma.
Source: The Economic Times - Category: Consumer Health News Source Type: news